TRα and TRβ remained to be predictive for five-year survival (TRα positivity—reduced five-year survival; TRβ positivity—advanced five-year survival) in breast cancer of non-specific type (TRα: p = 0.024; TRβ: p = 0.014), in high grade cancer (TRα: p = 0.042; TRβ: p = 0.005) and in patients aged younger than 42 years (TRα: p = 0.045; TRβ: p = 0.019). Here, THRB is linked to cancer.